Update and Future of Systemic Acne Treatment
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Systemic treatment is required in patients with moderate-to-severe acne, especially when acne scars start to occur. Antibiotics with anti-inflammatory properties, such as tetracyclines (oxytetracycline, tetracycline chloride, doxycycline, minocycline and limecycline) and macrolide antibiotics (erythromycin and azithromycin) are the agents of choice for papulopustular acne, even though the emerging resistant bacterial strains are minimizing their effect, especially regarding erythromycin. Systemic antibiotics should be administered during a period of 8–12 weeks. In severe papulopustular and in nodulocystic/conglobate acne, oral isotretinoin is the treatment of choice. Hormonal treatment represents an alternative regimen in female acne, whereas it is mandatory in resistant, severe pubertal or post-adolescent forms of the disease. Compounds with anti-androgenic properties include estrogens combined with progestins, such as ethinyl estradiol with cyproterone acetate, chlormadinone acetate, desogestrel, drospirenone, levonogestrel, norethindrone acetate, norgestimate, and other anti-androgens directly blocking the androgen receptor (flutamide) or inhibiting androgen activity at various levels, corticosteroids, spironolactone, cimetidine, and ketoconazole. After 3 months of treatment control of seborrhea and acne can be obtained. Low-dose corticosteroids (prednisone, prednisolone, or dexamethasone) are indicated in patients with adrenal hyperandrogenism or acne fulminans. New developments and future trends represent low-dose long-term isotretinoin regimens, new isotretinoin formulations (micronized isotretinoin), isotretinoin metabolites, combination treatments to reduce toxicity, insulin-sensitizing agents, 5α-reductase type 1 inhibitors, antisense oligonucleotide molecules, and, especially, new anti-inflammatory agents, such as lipoxygenase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cutaneous androgen metabolism: basic research and clinical perspectives
Chen, W., Thiboutot, D., & Zouboulis, C. C. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.00613.x · Cited by 273
Sebocytes are the key regulators of androgen homeostasis in human skin
Fritsch, M., Orfanos, C. E., & Zouboulis, C. C. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01312.x · Cited by 232
Self-citationIsotretinoin therapy for acne: results of a multicenter dose-response study
Strauss, J. S., Rapini, R. P., Shalita, A. R., Konecky, E., Pochi, P. E., Comite, H., & Exner, J. H. (1984) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(84)80100-0 · Cited by 223
Tsukada, M., Schröder, M., Orfanos, C. E., Zouboulis, C. C., Roos, T. C., Chandraratna, R. A. S., Reichert, U., & Merk, H. F. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00066.x · Cited by 212
Self-citationZouboulis, C. C., Korge, B., Akamatsu, H., Xia, L., Schiller, S., Gollnick, H., & Orfanos, C. E. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12471782 · Cited by 140
Self-citationEpidemiology of isotretinoin exposure during pregnancy
Dai, W. S., LaBraico, J. M., & Stern, R. S. (1992) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(92)70088-w · Cited by 133 · cited 1×
“Non-acne patients who have received oral isotretinoin therapy for seborrhea do not usually experience relapse for months or years. However, the duration of the sebostatic effect seems to be dose-dependent. Taking good tolerance into account, a dosage of 0.1–0.3 mg/kg/day over 4 weeks is sufficient to produce a sebosta…”
InfluentialIs Acne vulgaris a Genuine Inflammatory Disease?
Zouboulis, C. C. (2001) · Dermatology · doi:10.1159/000051771 · Cited by 130
Self-citationAcne fulminans: report of clinical findings and treatment of twenty-four patients
Karvonen, S.-L. (1993) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(93)70076-6 · Cited by 103 · cited 1×
“(fig. 2 , 3 , 4 ). Three to 4 weeks after administration of the drug, an apparent flare-up may occur with increased development of inflammatory lesions which usually do not require modification of the oral dose and improve spontaneously. Factors contributing to the need for longer treatment schedules include low dose…”
InfluentialThiboutot, D., Archer, D. F., Lemay, A., Washenik, K., Roberts, J., & Harrison, D. D. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01938-0 · Cited by 96
Orfanos, C. E., Adler, Y. D., & Zouboulis, C. C. (2000) · Hormone Research in Paediatrics · doi:10.1159/000053267 · Cited by 92 · cited 1×
“In addition, acne at puberty needs subsequent prophylactic medication and care over several years after clinical healing. Infantile and pediatric acne, androgenization signs in female patients with acne tarda [”
Self-citation
Cited by
Acne and sebaceous gland function
Zouboulis, C. C. (2004) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.03.004 · Cited by 561
Self-citationZouboulis, C., Chen, W.-C., Thornton, M., Qin, K., & Rosenfield, R. (2007) · Hormone and Metabolic Research · doi:10.1055/s-2007-961807 · Cited by 379
“Oral contraceptives are used in women with polycystic ovary syndrome or idiopathic hirsutism [41] ; both estrogens and progestins contribute to the androgen-suppressive effect [62, 80] .”
InfluentialSelf-citationNagy, I., Pivarcsi, A., Kis, K., Koreck, A., Bodai, L., McDowell, A., Seltmann, H., Patrick, S., Zouboulis, C. C., & Kemény, L. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.04.001 · Cited by 375
Self-citationFox, L., Csongradi, C., Aucamp, M., Du Plessis, J., & Gerber, M. (2016) · Molecules · doi:10.3390/molecules21081063 · Cited by 339
Nagy, I., Pivarcsi, A., Koreck, A., Széll, M., Urbán, E., & Kemény, L. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23705.x · Cited by 337
Metadata
- Authors
- Zouboulis, C. C., & Piquero-Martin, J.
- Venue
- Dermatology
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 206
- Issue
- 1
- Pages
- 37-53
- ISSN
- 1018-8665 (ISSN-L)
- 1421-9832
- OpenAlex
- W2099020836
- Cited by
- 155
- References
- 10
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update and Future of Systemic Acne Treatment. https://app.cochat.ai/papers/10.1159/000067821
- The paper
- Zouboulis, C. C., & Piquero-Martin, J. (2003). Update and Future of Systemic Acne Treatment. Dermatology. https://doi.org/10.1159/000067821
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.